VIYASH SCIENTIFIC
|
|
| BOM : 512529     NSE : VIYASH     | |
| LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 22,2026 |
|
Price(EOD): ₹ 271.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 11,853.10 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| VIYASH SCIENTIFIC | 1.9% | 1% | 28.7% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.7% | -2.3% | 8% |
| DIVIS LABORATORIES | 2% | -2.2% | 1.5% |
| TORRENT PHARMACEUTICALS | -1.8% | -0.1% | 36.7% |
| CIPLA | -2% | -3.3% | -9.9% |
| DR REDDYS LABORATORIES | -0.6% | -3.8% | -6.9% |
| MANKIND PHARMA | 1.5% | -6.4% | 1% |
| LUPIN | 3.5% | 3% | 16.4% |
| ZYDUS LIFESCIENCES | -1.6% | 2.9% | 10.2% |
FUNDAMENTAL ANALYSIS OF VIYASH SCIENTIFIC
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF VIYASH SCIENTIFIC
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
77.94
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 152.07 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 4.07
P/B Calculated based on Book Value of Rs 2,911.06 Cr
[Latest Year - Mar2026 - Consolidated Results ] 4.48
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 2,643.78 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
137% 121% 130% |
SHARE PRICE MOMENTUM OF VIYASH SCIENTIFIC
VIYASH SCIENTIFIC vs SENSEX
DEBT OF VIYASH SCIENTIFIC
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0.04 0.05 0.02 0.04 |
0.73 0.78 0.62 0.71 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF VIYASH SCIENTIFIC
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF VIYASH SCIENTIFIC
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
7.17% 4.91% 71.4% 36.81% |
19.12% 63.23% 441.63% 306.28% |
| QtrlyTrend |
8 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
VIYASH SCIENTIFIC related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 2.3% | 1.2% | 9.6% |
| BSE 1000 | 1.8% | 3.4% | 1.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | 3.8% | 10.1% | 6.2% |
| NIFTY SMALLCAP 500 | 3.3% | 7.8% | NA |
| NIFTY TOTAL MARKET | 1.7% | 3.3% | 1.8% |
You may also like the below Video Courses
FAQ about VIYASH SCIENTIFIC
Is VIYASH SCIENTIFIC good for long term investment?
As on Jun 22,2026, the Fundamentals of VIYASH SCIENTIFIC look Poor and hence it may not be good for long term investment ! See Financial Performance of VIYASH SCIENTIFIC . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is VIYASH SCIENTIFIC UnderValued or OverValued?
As on Jun 22,2026, VIYASH SCIENTIFIC is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of VIYASH SCIENTIFIC ?
As on Jun 22,2026, the Intrinsic Value of VIYASH SCIENTIFIC is Rs. 117.73 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 114.25
Fair Value [Median EV / Sales Model] : Rs. 122.89
Fair Value [Median Price / Sales Model] : Rs. 117.73
Estimated Median Fair Value of VIYASH SCIENTIFIC : Rs. 117.73
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.